A5037018787- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Cancer Genomics and Diagnostics
- Hematological disorders and diagnostics
- Neonatal Respiratory Health Research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Hemoglobinopathies and Related Disorders
- Fibroblast Growth Factor Research
- Proteoglycans and glycosaminoglycans research
- Polyomavirus and related diseases
- Nicotinic Acetylcholine Receptors Study
- Olfactory and Sensory Function Studies
- Retinoids in leukemia and cellular processes
- Vagus Nerve Stimulation Research
- Renal Transplantation Outcomes and Treatments
- Chemokine receptors and signaling
Cornell University
2024
NewYork–Presbyterian Hospital
2024
New York Hospital Queens
2024
Sheba Medical Center
2016-2023
Tel Aviv University
2008-2023
John Wiley & Sons (United States)
2021
Hudson Institute
2021
University of Pennsylvania
2015-2016
Tel Aviv Sourasky Medical Center
2006-2013
Weizmann Institute of Science
2010-2013
Abstract Gilteritinib is a potent and selective FLT3 kinase inhibitor with single-agent clinical efficacy in relapsed/refractory FLT3-mutated acute myeloid leukemia (AML). In this context, however, gilteritinib not curative, response duration limited by the development of secondary resistance. To evaluate resistance mechanisms, we analyzed baseline progression samples from patients treated on trials gilteritinib. Targeted next-generation sequencing at time AML identified treatment-emergent...
Abstract Background Non-T-cell depleted haploidentical hematopoietic stem cell transplantation (HaploSCT) is being increasingly used in acute lymphoblastic leukemia (ALL) with improving patient outcomes. We have recently reported that outcomes of adult patients (pts) ALL complete remission (CR) receiving HaploSCT are comparable to unrelated donor transplants. now compared and matched sibling (MSD) transplants pts ALL. Aim To assess MSD CR. Methods retrospectively analyzed (≥ 18 years) who...
BackgroundMicroRNA-132 (miR-132) targets acetylcholinesterase (AChE) and potentiates the cholinergic blockade of inflammatory reactions in cultured cells experimental mice, but implications this interaction to human disease remained unexplored. This study aimed test whether miR-132 is causally involved anti-inflammatory patients with bowel (IBD) modulates vagal tone consequently inflammation IBD.
Highlights•Patients age ≥70 years with acute myelogenous leukemia have a 2-year survival after hematopoietic stem cell transplantation of 38%.•Patients Karnofsky Performance Status score ≥80% had better survival.•Survival was worse in patients compared 50 to 69 years.ABSTRACTReduced-intensity conditioning (RIC) allows for the use allogeneic (HSCT) older (AML). We outcomes between 713 and 16,161 who underwent HSCT 2004 2014. A higher proportion were male secondary AML, active disease,...
Abstract Haploidentical hematopoietic cell transplantation (haplo‐HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or unrelated donors are unavailable. As several potential haploidentical relative typically available for a given patient, optimizing donor selection to improve clinical outcome crucial. The impact of age and kinship on the not clearly established this setting. Using multinational registry working party...
Key Points Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy may promote genetic evolution drug resistance.
A significant proportion of hematopoietic stem cell transplants are performed with ABO-mismatched donors. The impact ABO mismatch on outcome following transplantation remains controversial and there no published data regarding the in acute myeloid leukemia patients receiving haploidentical transplants. Using European Blood Marrow Transplant Acute Leukemia Working Group registry we identified 837 who underwent transplantation. Comparative analysis was between received ABO-matched versus for...
Summary Patients with FLT3 ‐mutated acute myeloid leukaemia (AML) that relapse or are refractory (R/R) to intensive induction have poor outcomes. Gilteritinib has recently become standard‐of‐care for patients R/R AML. We investigated whether adding venetoclax gilteritinib (gilt‐ven) improves outcomes as compared monotherapy. included treated ( n = 19) and gilt‐ven 17) AML after chemotherapy. groups did not differ in terms of mCRc rates (53% 65%, p 0.51) realization allogeneic haematopoietic...
Abstract The optimal conditioning regimen to employ before hematopoietic stem cell transplantation in acute lymphoblastic leukemia (ALL) is still undecided, and while cyclophosphamide/total body irradiation (Cy/TBI) the most commonly used myeloablative regimen, there are concerns regarding long‐term toxicity for patients conditioned with this regimen. Thiotepa‐based an emerging radiation‐free recent publications indicative of comparable clinical outcomes TBI‐based conditioning. In analysis...
Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years.To assess the incremental improvement of transplanted AML last two decades.Patients included this analysis were adult who underwent allo-SCT from an HLA-matched sibling donor (MSD) or unrelated (MUD) first remission. Patient outcomes assessed between three cohorts according to year transplant (1993-2002, 2003-2007 and 2008-2012).The...
Posttransplant cyclophosphamide (PTCy) is increasingly being utilized as a principle GvHD prophylaxis strategy in allogeneic hematopoietic cell transplantation (allo-HCT). A haploidentical (haplo) or matched unrelated donor (UD) valid option the absence of related donor.We compared outcomes patients with acute leukemia who underwent haplo bone marrow (haplo-BM, N = 401) versus UD mobilized peripheral blood stem cells (UD-PB, 192) setting PTCy.The median follow-up duration was 36 months...
Abstract Combinations of the BCL‐2 inhibitor, venetoclax, with either hypomethylating agents (HMA) or low dose cytarabine (LDAC), have shown promising results in clinical trials AML patients unfit for intensive therapy. We report on efficacy and safety venetoclax combinations treated outside trials. Complete remission (CR) + CR incomplete count recovery (CRi) were achieved 61% patients, similar CR+CRi rates secondary AML, who previously HMA (61% 43%, respectively). Relapse occurred 25% a...
Summary Assessment of minimal residual disease ( MRD ) is being routinely used to assess response in patients with acute myeloid leukaemia AML ). While it well established that pre‐transplant positive studies predict for relapse transplanted either from matched sibling donors or unrelated donors, currently unknown whether has comparable prognostic value haploidentical stem cell transplantation (haplo‐ SCT To this end we performed a retrospective analysis using the Acute Leukaemia Working...
The French, American, and British (FAB) classification system for acute myeloid leukemia (AML) is extensively used incorporated into the AML, not otherwise specified (NOS) category in 2016 WHO edition of neoplasm classification. While recent data proposes that FAB does provide additional prognostic information patients whom NPM1 status available, it unknown whether still retains a current role predicting outcome AML undergoing allogeneic stem cell transplantation. Using European Society...
// Gabrielle Roth-Guepin 1, * , Jonathan Canaani 2, Annalisa Ruggeri 3 Myriam Labopin 3, 4, 5 Juergen Finke 6 Jan J. Cornelissen 7 Jeremy Delage 8 Gernot Stuhler 9 Monserrat Rovira 10 Mike Potter 11 Michael Stadler 12 Hendrik Veelken 13 Jean Yves Cahn 14 Matthew Collin 15 Beguin 16 Sebastian Giebel 17 Arnon Nagler # and Mohamad Mohty 5, 1 Hematology Department, CHU Brabois, Nancy, France 2 Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Aviv, Israel Acute Leukemia Working...
Second allogeneic hematopoietic stem-cell transplantation (HSCT2) is a therapeutic option for patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) relapsing after first transplant (HSCT1). However, allocated to HSCT2 may be selected group better prognosis and the added efficacy of not well established. We retrospectively analyzed 407 consecutive relapsed AML/MDS HSCT1. Sixty-two had (15%) 345 did not. The 2-year cumulative incidence rates non-relapse mortality relapse...